https://www.bioworld.com/rss en-us Eyeing a potential drug launch early next year, Apnimed Inc. has entered the public market via an upsized IPO, pricing 12 million shares at $16 apiece for gross proceeds of $192 million. Another $24 million could come if underwriters exercise their overallotment option for an additional 1.5 million shares. http://www.bioworld.com/articles/733034 Fri, 31 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733034-with-sleep-apnea-drug-under-review-apnimed-prices-192m-ipo IPO, coins, financial chart Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem. http://www.bioworld.com/articles/733044 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/733044-taiwan-biotech-looks-outward-in-next-phase-of-growth Lee-Cheng Liu, chairman, Taiwan BIO Lee-Cheng Liu, chairman, Taiwan BIO Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem. http://www.bioworld.com/articles/732918 Mon, 27 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732918-taiwan-biotech-looks-outward-in-next-phase-of-growth Lee-Cheng Liu, chairman, Taiwan BIO Lee-Cheng Liu, chairman, Taiwan BIO Tidalsense Ltd. raised $19 million in a funding round for N-Tidal Diagnose, its AI-based diagnostic platform, which can identify chronic obstructive pulmonary disease (COPD) in as little as five minutes. The test requires an individual to breathe normally into a handheld device for 75 seconds and it captures a carbon dioxide breath waveform, which is analyzed by AI to detect COPD. The funds will be used to support commercialization in the U.K., Ireland and Europe, on preparations for U.S. market entry and for expansion of the platform into additional respiratory conditions, including asthma. http://www.bioworld.com/articles/732917 Mon, 27 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732917-tidalsense-raises-19m-for-ai-powered-copd-diagnostic-platform Tidalsense N-Tidal Diagnose N-Tidal Diagnose, an AI-based diagnostic platform for COPD. Credit: Tidalsense Ltd. Shijiazhuang Yiling Pharmaceutical Co. Ltd. has divulged new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists potentially useful for the treatment of pulmonary fibrosis. http://www.bioworld.com/articles/732887 Thu, 23 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732887-shijiazhuang-yiling-pharmaceutical-synthesizes-new-lpar1-antagonists Teikyo University has synthesized new neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of acute lung injury. http://www.bioworld.com/articles/732791 Mon, 20 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732791-teikyo-university-discloses-new-neutrophil-elastase-inhibitors Insmed Inc. has delivered further evidence of the advantages of its once-daily pulmonary arterial hypertension (PAH) drug TPIP (treprostinil palmitil inhalation powder), with data from an open-label extension of the phase IIb trial showing patients in the treated arm maintained the benefits over 24 months. http://www.bioworld.com/articles/732724 Fri, 17 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732724-open-label-extension-drives-home-benefits-of-insmeds-pah-therapy Lungs GSK plc’s walk-away from refractory chronic cough prospect camlipixant because of dicey phase III results opened the door wider for Trevi Therapeutics Inc. with Haduvio (oral nalbuphine ER), which yielded positive phase II data in June. Shares of Trevi (NASDAQ:TRVI) closed July 17 at $19.07, up $1.71, or 9.9%. London-based GSK reported findings with camlipixant, a P2X3 receptor antagonist, from the Calm-1 and Calm-2 trials. The first met its primary endpoint, with camlipixant 50 mg twice daily showing statistically significant reductions in 24-hour cough frequency vs. placebo when measured at week 12. http://www.bioworld.com/articles/732722 Fri, 17 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732722-cant-hack-it-bellus-tolls-for-gsk-phase-iii-cough-drug Man coughing into hand A joint Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. patent details new tetrahydrobenzothiazole compounds potentially useful for the treatment of allergic asthma. http://www.bioworld.com/articles/732658 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732658-jiangsu-hengrui-shanghai-senhui-and-shanghai-shengdi-patent-new-compounds-for-asthma Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732665 Tue, 14 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732665-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background Guangzhou Respiratory Medicine Engineering Technology Co. Ltd. has disclosed new cathepsin C (dipeptidyl peptidase I) and neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of asthma, diabetes, psoriasis, nasal polyps, cystic fibrosis and more. http://www.bioworld.com/articles/732574 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732574-guangzhou-respiratory-medicine-patents-new-cathepsin-c-neutrophil-elastase-inhibitors Acute lung injury (ALI) is an inflammatory pulmonary disease mainly caused by infection. It can progress to the life-threatening condition acute respiratory distress syndrome (ARDS). ALI/ARDS account for a high mortality rate of about 40%. Elucidating the mechanisms behind ALI/ARDS is crucial for developing new therapeutics. http://www.bioworld.com/articles/732504 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732504-usp43-targeting-protects-against-acute-lung-injury Lungs wireframe illustration Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary. http://www.bioworld.com/articles/732430 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732430-astrazeneca-nabs-pde3-4-inhibitor-for-copd-in-21b-sino-deal Red lungs on blue background One company was looking to add to its royalty stream and R&D portfolio. The other was seeking strategic alternatives in the wake of clinical misfires over the last few years. In an agreement aimed at satisfying both goals, Zymeworks Inc. will acquire Theravance Biopharma Inc., paying $17 per share, or about $929 million, though the transaction is structured in a way that minimizes the former’s current capital position. http://www.bioworld.com/articles/732226 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732226-zymeworks-bolsters-royalty-stream-with-theravance-buy Acquisition puzzle ALK5 mediates the core profibrotic TGF-β signaling cascade that promotes fibroblast activation, myofibroblast differentiation and extracellular matrix production, ultimately leading to persistent tissue remodeling and lung fibrosis. http://www.bioworld.com/articles/732207 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732207-inhaled-alk5-inhibitor-delivers-lung-targeted-antifibrotic-effects Digital lungs illustration The outbreak of hantavirus infection first reported on the MV Hondius cruise ship on May 2 is all but over, with most isolating passengers, crew members and other contacts leaving quarantine over the past week, as the 42-day incubation period drew to an end. http://www.bioworld.com/articles/732078 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732078-who-to-declare-hantavirus-outbreak-over-as-quarantines-end Hantavirus cells Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. http://www.bioworld.com/articles/732184 Wed, 24 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732184-pulmonary-inflammation-unveils-three-severe-pneumonia-subtypes Lungs anatomy The industry is stepping up its campaign to persuade European governments to increase their drugs budgets, in what is described as a landmark report making the case that spending on patented drugs is not a cost to be contained, but an investment in health and the economy. http://www.bioworld.com/articles/732066 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732066-efpia-report-every-1-spent-on-new-drugs-returns-567-to-europes-economy Pill with Euro currency symbol Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. Some patients with severe pneumonia progress in different ways. Predicting their trajectories could help tailor treatments and prevent fatal outcomes. To do this, the scientists analyzed bronchoalveolar fluid from several patient cohorts and identified three biological pneumotypes based on which cells are present, which genes are active, and which inflammatory proteins are produced. http://www.bioworld.com/articles/732108 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732108-pulmonary-inflammation-unveils-three-severe-pneumonia-subtypes Lungs anatomy Idiopathic pulmonary fibrosis (IPF), a chronic, progressive disease of unknown etiology, is the most common and fatal interstitial lung disease. Currently available treatments for IPF, such as pirfenidone and nintedanib, can slow disease progression and reduce mortality in patients who can tolerate them. However, these drugs frequently cause significant side effects and have been unable to improve quality of life in pivotal trials, which highlights the critical need for discovering novel IPF treatment strategies. http://www.bioworld.com/articles/731996 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731996-dual-autotaxin-inhibitor-ppar-agonist-alleviates-pulmonary-fibrosis-in-vivo AI-generated image of illustration of MRI of lungs with fibrosis After raising HK$1.255 billion (US$160 million) in its IPO on the Hong Kong Stock Exchange earlier this month, Longbio Pharma Co. Ltd.’s lead candidate, LP-003, met the primary endpoint of total nasal symptom scores during peak pollen season in moderate to severe seasonal allergic rhinitis. http://www.bioworld.com/articles/731980 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731980-longbios-lp-003-meets-phase-iii-allergy-endpoints Woman holding tissue to nose with plants, pollen After raising HK$1.255 billion (US$160 million) in its IPO on the Hong Kong Stock Exchange earlier this month, Longbio Pharma Co. Ltd.’s lead candidate, LP-003, met the primary endpoint of total nasal symptom scores during peak pollen season in moderate to severe seasonal allergic rhinitis. http://www.bioworld.com/articles/731878 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731878-longbios-lp-003-meets-phase-iii-allergy-endpoints Woman holding tissue to nose with plants, pollen The microbiome and a frontline innate antimicrobial sensor, Toll-like receptor 5 (TLR5), play an essential role in the development of idiopathic pulmonary fibrosis (IPF). A scientific collaboration led by researchers at the National Institute of Environmental Health Sciences has revealed how TLR5 protects against fibrosis through its ability to modulate the lung microbiome. Their study also shows that activating TLR5 protects against fibrosis and corrects pulmonary dysbiosis. http://www.bioworld.com/articles/731651 Thu, 04 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731651-innate-immunity-and-microbiome-allied-against-pulmonary-fibrosis Illustration of therapies for lung diseases Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody. http://www.bioworld.com/articles/731646 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731646-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731648 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731648-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody. http://www.bioworld.com/articles/731445 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731445-longbio-to-raise-hk14b-in-hong-kong-ipo-for-immunology-work HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for the targeted class of cancer therapeutics. http://www.bioworld.com/articles/731444 Thu, 28 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731444-trop2-adcs-progress-into-first-line-for-lung-breast-cancers Floating antibody drug conjugates Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients. http://www.bioworld.com/articles/731473 Thu, 28 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731473-new-evidence-links-autoimmunity-to-long-covid-symptoms Illustration of antibodies and viral infection Oorja Bio Inc., named after the phonetic spelling of “energy” in Sanskrit, secured $30 million from founding investor Westlake Biopartners in a series A financing round to advance its in-licensing approach to develop drugs for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases. http://www.bioworld.com/articles/731387 Fri, 22 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731387-newco-news-oorja-energizes-with-30m-for-ipf Heart and lungs As generic versions of its blockbuster drug Ofev (nintedanib) start to hit the market, Boehringer Ingelheim GmbH looks to have swerved the patent cliff, with European and Japanese regulators both approving a potential replacement, Jascayd (nerandomilast), this week. At its monthly meeting, the EMA’s Committee for Medicinal Products for Human Use also recommended Novartis AG’s Vijoice (alpelisib) be given conditional approval in the treatment of PIK3CA-related overgrowth spectrum disorders. http://www.bioworld.com/articles/731385 Fri, 22 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731385-ema-poised-to-be-4th-regulator-approving-boehringers-jascayd-lung-drug Jascayd Credit: Boehringer Ingelheim GmbH